AMEX:NSPR

Stock Analysis Report

Executive Summary

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has InspireMD's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

9.0%

NSPR

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

-88.9%

NSPR

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned 10% over the past year.

Return vs Market: NSPR underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

NSPRIndustryMarket
7 Day9.0%3.2%3.4%
30 Day-57.2%-1.8%-1.0%
90 Day-63.0%-0.4%-0.4%
1 Year-88.9%-88.9%10.9%10.0%7.7%5.4%
3 Year-100.0%-100.0%69.9%64.8%46.2%36.8%
5 Year-100.0%-100.0%128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is InspireMD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InspireMD undervalued compared to its fair value and its price relative to the market?

0.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NSPR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: NSPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate NSPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NSPR is good value based on its PB Ratio (0.3x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is InspireMD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

106.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NSPR's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if NSPR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NSPR's revenue (106.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: NSPR's revenue (106.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if NSPR's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has InspireMD performed over the past 5 years?

23.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NSPR is unprofitable, but has reduced losses over the past 5 years at a rate of 23.1% per year.

Accelerating Growth: Unable to compare NSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NSPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: NSPR has a negative Return on Equity (-172.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NSPR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NSPR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is InspireMD's financial position?


Financial Position Analysis

Short Term Liabilities: NSPR's short term assets ($7.2M) exceeds its short term liabilities ($1.9M)

Long Term Liabilities: NSPR's short term assets (7.2M) exceeds its long term liabilities (1.8M)


Debt to Equity History and Analysis

Debt Level: NSPR is debt free.

Reducing Debt: NSPR currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: NSPR has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NSPR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NSPR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NSPR has less than a year of cash runway if free cash flow continues to reduce at historical rates of -5.1% each year


Next Steps

Dividend

What is InspireMD's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NSPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NSPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NSPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of InspireMD's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Jim Barry (60yo)

3.3yrs

Tenure

US$649,530

Compensation

Dr. James J. Barry, also known as Jim, Ph.D., has been the Chief Executive Officer and President of InspireMD, Inc. since June 06, 2016 and served as its Executive Vice President and Chief Operating Office ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jim's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

60yo

Average Age

Experienced Management: NSPR's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

4.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: NSPR's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1211 Dec 18
Osiris Capital Management
EntityCompany
Shares1.3
Max PriceUS$8.88
SellUS$226 Nov 18
Thomas Kester
EntityIndividual
Role
Member of the Board of Directors
Director
Shares0.16
Max PriceUS$10.50

Ownership Breakdown


Management Team

  • Sol Barer (72yo)

    Special Advisor to the Board

    • Tenure: 2.3yrs
    • Compensation: US$13.92k
  • Jim Barry (60yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$649.53k
  • Craig Shore (58yo)

    CFO, Chief Administrative Officer

    • Tenure: 8.6yrs
    • Compensation: US$463.37k
  • Roei Samuri

    Vice President of Operations

    • Tenure: 0.8yrs

Board Members

  • Mike Berman (61yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$34.00k
  • Elazer Edelman

    Member of Advisory Board

    • Tenure: 0yrs
  • Thomas Kester (72yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$41.00k
  • Antonio Colombo

    Member of Advisory Board

    • Tenure: 0yrs
  • Alexandre Abizaid

    Member of Advisory Board

    • Tenure: 0yrs
  • Eberhart Grube

    Member of Advisory Board

    • Tenure: 0yrs
  • Paul Stuka (64yo)

    Chairman of the Board

    • Tenure: 2.3yrs
    • Compensation: US$44.93k
  • Yaron Almagor

    Member of Advisory Board

    • Tenure: 0yrs
  • Edo Kaluski

    Member of Advisory Board

    • Tenure: 0yrs
  • Jim Barry (60yo)

    President

    • Tenure: 3.3yrs
    • Compensation: US$649.53k

Company Information

InspireMD, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InspireMD, Inc.
  • Ticker: NSPR
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.387m
  • Shares outstanding: 1.94m
  • Website: https://www.inspiremd.com

Number of Employees


Location

  • InspireMD, Inc.
  • 4 Menorat Hamaor Street
  • Tel Aviv
  • 6744832
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NSPRAMEX (NYSE MKT LLC)YesCommon StockUSUSDApr 2011
II2QDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2011

Biography

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The compan ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:11
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.